Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B

12 Mar 2021

Abstract excerpt

Abstract Tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 have revolutionized therapy for chronic myeloid leukemia (CML), paving the way for clinical development in other diseases. Despite success, targeting leukemic stem cells and overcoming drug resistance remain challenges for curative cancer therapy. To identify drivers of kinase-independent TKI resistance in CML, we performed genome-wide expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33712704
DOI: 10.1038/s41388-021-01732-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa BPMID 33712704Read ↗

26S Proteasome Non-ATPase Regulatory Subunits 1 (PSMD1) and 3 (PSMD3) as Putative Targets for Cancer Prognosis and TherapySemantic proximity Read ↗

19S Proteasome Subunits as Oncogenes and Prognostic Biomarkers in FLT3-Mutated Acute Myeloid Leukemia (AML).Semantic proximity Read ↗

Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human LeukemiaSemantic proximity Read ↗

Inhibition of NF-κB Signaling Alters Acute Myelogenous Leukemia Cell TranscriptomicsSemantic proximity Read ↗

Targeting NLRP3 inhibits AML progression by inducing PERK/eIF2-mediated apoptosisSemantic proximity Read ↗

The NLRP3/eIF2 axis drives cell cycle progression in acute myeloid leukemiaSemantic proximity Read ↗

NF-κB: A Druggable Target in Acute Myeloid LeukemiaSemantic proximity Read ↗

Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia.Semantic proximity Read ↗

Bioinformatics analysis and identification of hub genes and immune-related molecular mechanisms in chronic myeloid leukemiaSemantic proximity Read ↗

Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemiaSemantic proximity Read ↗

Activation of targetable inflammatory immune signaling is seen in Myelodysplastic Syndromes with SF3B1 mutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.